We examined proliferation markers Ki-67 and proliferating cell nuclear antigen (PCNA) to determine whether immunohistochemical staining results could predict outcome in 22 uterine papillary serous carcinomas (UPSC). Eighteen tumors (82%) had increased proliferation as demonstrated by Ki-67 immunostaining with 50% of these patients dying of disease. Twenty tumors (91%) showed high PCNA immunoreactivity; 60% of these patients died of disease. Most UPSC exhibit high immunoreactivity to Ki-67 and/or PCNA, which showed no correlation with outcome or stage. These results may reflect the aggressive clinical behavior of UPSC. We conclude that Ki-67 and PCNA immunohistochemistry have limited use as prognostic indicators in UPSC.
1. Hendrickson M, Ross J, Eifel P, Martinez A, Kempson R. Uterine papillary serous carcinoma: A highly malignant form of endometrial adenocarcinoma. Am J Surg Pathol6:93-108, 1982
2.
2. Karpas C, Bridge M. Endometrial adenocarcinoma with psammomatous bodies. Am J Obstet Gynecol87:935-941, 1963
3.
3. LiVolsi V. Adenocarcinoma of the endometrium with psammoma bodies. Obstet Gynecol50:725-728, 1977
4.
4. Abeler V, Kjorstad K. Serous papillary carcinoma of the endometrium: A histopathological study of 22 cases. Gynecol Oncol39:266-271, 1990
5.
5. O'Hanlan K, Levine P, Harbatkin D, Feiner C, Goldberg G, Jones J, Rodriguez-Rodriguez L. Virulence of papillary endometrial carcinoma. Gynecol Oncol37:112-119, 1990
6.
6. Sutton G, Brill L, Michael H, Stehman F, Ehrlich C. Malignant papillary lesions of the endometrium. Gynecol Oncol27:294-304, 1987
7.
7. Dunton C, Balsara G, McFarland M, Hernandez E. Uterine papillary serous carcinoma: A review. Obstet Gynecol Surv46:97-102, 1991
8.
8. Goff B, Kato D, Schmidt R, Ek M, Ferry J, Muntz H, Cain J, Tamimi H, Figge D, Greer B. Uterine papillary serous carcinoma: Patterns of metastatic spread. Gynecol Oncol54:264-268, 1994
9.
9. Jeffrey J, Krepart G, Lotocki R. Papillary serous adenocarcinoma of the endometrium. Obstet Gynecol67:670-674, 1986
10.
10. Lee K, Belinson J. Recurrence in noninvasive endometrial carcinoma. Relationship to uterine papillary serous carcinoma. Am J Surg Pathol15:965-973, 1991
11.
11. Sherman M, Bitterman P, Rosenshein N, Delgado G, Kurman R. Uterine serous carcinoma: A morphologically diverse neoplasm with unifying clinicopathologic features. Am J Surg Pathol16:600-610, 1992
12.
12. Rosenberg P, Blom R, Hogberg T, Simonsen E. Death rate and recurrence pattern among 841 clinical stage I endometrial cancer patients with special reference to uterine papillary serous carcinoma. Gynecol Oncol51:311-315, 1993
13.
13. Christman J, Kapp D, Hendrickson M, Howes A, Ballon S. Therapeutic approaches to uterine papillary serous carcinoma: A preliminary report. Gynecol Oncol26:228-235, 1987
14.
14. Chambers J, Merino M, Kohorn E, Peschel R, Schwartz P. Uterine papillary serous carcinoma. Obstet Gynecol69:109-113, 1987
15.
15. Levenback C, Burke T, Silva E, Morris M, Gershenson D, Kavanaugh J, Wharton J. Uterine papillary serous carcinoma (UPSC) treated with cisplatin, doxorubicin and cyclophosphamide (PAC). Gynecol Oncol46:317-321, 1992
16.
16. Yu C, Woods A, Levison D. The assessment of cellular proliferation by immunohistochemistry: A review of currently available methods and their applications. Histochem J24:121-131, 1992
17.
17. Yu C, Filipe M. Update on proliferation-associated antibodies applicable to formalin-fixed paraffin-embedded tissue and their clinical applications. Histochem J25:843-853, 1993
18.
18. Hartmann L, Thomas T, Kamel N, Podratz K, Cha S, Wieand S, Keeney G, Roche P. Proliferating cell nuclear antigen in epithelial ovarian cancer: Relation to results at second-look laparotomy. Gynecol Oncol47:191-195, 1992
19.
19. Lipponen P, Eskelinen M. Cell proliferation of transitional cell bladder tumors determined by PCNA/cyclin immunostaining and its prognostic value. Br J Cancer66:171-176, 1992
20.
20. Yu C, Hall P, Fletcher C, Camplejohn R, Waseem N, Lane D, Levison D. Haemangiopericytomas. The prognostic value of immunohistochemical staining with a monoclonal antibody to proliferating cell nuclear antigen. Histopathol19:29-33, 1991
21.
21. McCormick D, Chong H, Hobbs C, Datta C, Hall P. Detection of the Ki-67 antigen in fixed and wax-embedded sections with the monoclonal antibody MIB 1. Histopathology22:355-360, 1993
22.
22. Key G, Petersen J, Becker M, Duchrow M, Schluter C, Askaa J, Geredes J. New antiserum against Ki-67 antigen suitable for double immunostaining of paraffin wax sections. J Clin Pathol46:1080-1084, 1993
23.
23. Scott R, Hall P, Haldane J, Van Noorden S, Price Y, Lane D, Wright N. A comparison of immunohistochemical markers of cell proliferation with experimentally determined growth fraction. J Pathol165: 173-178, 1991
24.
24. Isola J, Kallioniemi O, Korte J, Wahlstrom T, Aine R, Helle M, Helin H. Steroid receptors and Ki-67 reactivity in ovarian cancer and in normal ovary: Correlation with DNA flow cytometry, biochemical receptor assay and patient survival. J Pathol162: 295-301, 1990
25.
25. Albers P, Orazi A, Ulbright T, Miller G, Haidar J, Donohue J, Foster R. Prognostic significance of immunohistochemical proliferation markers (Ki-67/MIB1 and proliferation-associated nuclear antigen), p53 protein accumulation and neovascularization in clinical stage A nonseminomatous testicular germ cell tumors. Modern Pathol8:492-497, 1995
26.
26. Hall P, Richards M, Gregory W, d'Ardenne A, Lister T,Stansfeld A. The prognostic value of Ki67 immunostaining in non-Hodgkin's lymphoma. J Pathol154:223-235, 1988
27.
27. Linden M, Torres F, Kubus J, Zarbo R. Clinical application of morphologic and immunocytochemical assessments of cell proliferation. Am J Clin Pathol97 (Suppl 1):S4-S13, 1992
28.
28. Hall P, Levison D, Woods A, Yu C, Kellock D, Watkins J, Barnes D, Gillett C, Camplejohn R, Dover R, Waseem N, Lane D. Proliferating cell nuclear antigen (PCNA) immunolocalization in paraffin sections: An index of cell proliferation with evidence of deregulated expression in some neoplasms. J Pathol162:285-294, 1990
29.
29. Dervan P, Magee H, Buckley C, Carney D. Prolferating cell nuclear antigen counts in formalin-fixed paraffin-embedded tissue correlate with Ki-67 in fresh tissue. Am J Clin Pathol97 (Suppl 1):S21-S28, 1992
30.
30. Kamel O, LeBrun D, Davis R, Berry G, Warnke R. Growth factor estimation of malignant lymphomas in formalin-fixed paraffin-embedded tissue using anti-PCNA/cyclin 19A2. Am J Pathol138:1471-1477, 1991
31.
31. Leonardi E, Girlando S, Serio G, Mauri F, Perrone G, Scampini S, Palma P, Barbareschi M. PCNA and Ki-67 expression in breast carcinoma: Correlations with clinical and biological variables. J Clin Pathol45:416-419, 1992
